PKCδ as a Target for Chemotherapeutic Drugs

C. Brodie, Stephanie L. Lomonaco

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review


PKCd, a member of the novel PKC family, has been widely implicated as mediator of apoptosis in response to phorbol esters and chemotherapeutic agents, and it is differentially expressed in various human cancer types. A characteristic of PKCd is that it is regulated by tyrosine phosphorylation, and in some cases this post-translational modification seems to be essential for the response to stimuli. PKCd may be an attractive target for cancer therapeutics.
Original languageAmerican English
Title of host publicationProtein Kinase C in Cancer Signaling and Therapy
EditorsMarcelo G. Kazanietz
PublisherHumana Press
ISBN (Print)978-1-60761-543-9
StatePublished - 2010

Publication series

NameCurrent Cancer Research


Dive into the research topics of 'PKCδ as a Target for Chemotherapeutic Drugs'. Together they form a unique fingerprint.

Cite this